These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35778852)

  • 21. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    Archin NM; Keedy KS; Espeseth A; Dang H; Hazuda DJ; Margolis DM
    AIDS; 2009 Sep; 23(14):1799-806. PubMed ID: 19590405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
    Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
    Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation.
    Albert BJ; Niu A; Ramani R; Marshall GR; Wender PA; Williams RM; Ratner L; Barnes AB; Kyei GB
    Sci Rep; 2017 Aug; 7(1):7456. PubMed ID: 28785069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV latency reversal agents: A potential path for functional cure?
    Lopes JR; Chiba DE; Dos Santos JL
    Eur J Med Chem; 2021 Mar; 213():113213. PubMed ID: 33540228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.
    Savarino A; Mai A; Norelli S; El Daker S; Valente S; Rotili D; Altucci L; Palamara AT; Garaci E
    Retrovirology; 2009 Jun; 6():52. PubMed ID: 19486542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Latency Reversal Agents for HIV-1 Cure.
    Spivak AM; Planelles V
    Annu Rev Med; 2018 Jan; 69():421-436. PubMed ID: 29099677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
    Shan L; Xing S; Yang HC; Zhang H; Margolick JB; Siliciano RF
    J Antimicrob Chemother; 2014 Jan; 69(1):28-33. PubMed ID: 23999005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
    Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
    J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway.
    Lu W; Yang C; Xu X; Chen C; Hou X; Fang H; Liu S
    Life Sci; 2021 Feb; 267():118427. PubMed ID: 32941894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective HDAC inhibition for the disruption of latent HIV-1 infection.
    Barton KM; Archin NM; Keedy KS; Espeseth AS; Zhang YL; Gale J; Wagner FF; Holson EB; Margolis DM
    PLoS One; 2014; 9(8):e102684. PubMed ID: 25136952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir.
    Dai W; Wu F; McMyn N; Song B; Walker-Sperling VE; Varriale J; Zhang H; Barouch DH; Siliciano JD; Li W; Siliciano RF
    Sci Transl Med; 2022 Oct; 14(667):eabh3351. PubMed ID: 36260688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Latency Reversal 2.0: Giving the Immune System a Seat at the Table.
    Singh V; Dashti A; Mavigner M; Chahroudi A
    Curr HIV/AIDS Rep; 2021 Apr; 18(2):117-127. PubMed ID: 33433817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.
    Matalon S; Rasmussen TA; Dinarello CA
    Mol Med; 2011; 17(5-6):466-72. PubMed ID: 21424110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Cillo AR; Sobolewski MD; Bosch RJ; Fyne E; Piatak M; Coffin JM; Mellors JW
    Proc Natl Acad Sci U S A; 2014 May; 111(19):7078-83. PubMed ID: 24706775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.
    Manson McManamy ME; Hakre S; Verdin EM; Margolis DM
    Antivir Chem Chemother; 2014 Jan; 23(4):145-9. PubMed ID: 24318952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir.
    Covino DA; Desimio MG; Doria M
    Sci Rep; 2022 Nov; 12(1):18567. PubMed ID: 36329160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.